Pere Fusté

ORCID: 0000-0002-8129-9897 · 4 papers in corpus
diagnostic-accuracy 2024
O-RADS MRI scoring system: key points for correct application in inexperienced hands
Insights into imaging ·doi:10.1186/s13244-024-01670-3

OBJECTIVES: To evaluate the efficacy of the O-RADS MRI criteria in the stratification of risk of malignancy of solid or sonographically indeterminate ovarian masses and assess the interobserver agreement of this classification between exper…

nonrandomized-trial 2023
Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement
Gynecologic Oncology ·doi:10.1016/j.ygyno.2023.11.007

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial …

diagnostic-accuracy 2022
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
Diagnostics (Basel, Switzerland) ·doi:10.3390/diagnostics12010226

(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively identify epithelial ovarian cancer (EOC) or metastatic cancer in the ovary (MCO). (2) METHODS: single center retrospective study, including…

observational 2021
HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected
The Journal of international medical research ·doi:10.1177/03000605211047701

OBJECTIVE: To analyze the utility of carbohydrate antigen (CA)125 and human epididymis protein 4 (HE4) to detect malignancy in women with ovarian endometriosis, when ovarian cancer is suspected and ultrasonography results are inconclusive. …